多重用药组合的多轨迹与衰弱分层下的临床结局:纵向队列研究
该研究基于台湾全民健康保险数据库,对787 072名多重用药老年人采用组基多轨迹模型识别出三种用药组合模式,并分析其与6年全因死亡、住院及骨折住院风险的关系。结果显示,以症状治疗药物为主的模式与更高的不良结局风险相关,且风险差异随衰弱程度增加而减弱,但骨折住院风险例外。
要点
- 识别出三种多重用药组合模式:心血管代谢药物主导、症状治疗药物主导、两者共同主导。
- 风险差异随衰弱程度增加而减弱,但骨折住院风险未见减弱。
核心结论
- 以症状治疗药物为主的多重用药模式与更高的全因死亡、全因住院、非计划住院和骨折住院风险相关。
- 上述风险差异随衰弱程度增加而普遍减弱,但骨折住院风险例外。
研究设计与样本
- 基于台湾全民健康保险研究数据库的纵向队列研究。
- 纳入787 072名多重用药老年人,平均(SD)年龄76.2(7.0)岁,男性361 767人(46.0%)。
- 采用组基多轨迹模型识别2年内的多重用药组合轨迹,并用Cox比例风险模型评估6年结局风险。
主要发现
- 所有组的用药模式在2年轨迹期内保持稳定。
临床怎么用
- 对多重用药老年人应关注用药组合模式,尤其是症状治疗药物占比较高的模式,可能提示不良结局风险增加。
- 在衰弱程度较高的老年人中,用药组合模式与不良结局的风险差异减弱,但骨折风险仍需关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While polypharmacy is prevalent among older adults, the impact of different medication composition patterns on clinical outcomes and how these associations vary by frailty status remains unclear. We aimed to identify distinct longitudinal patterns of polypharmacy composition and clinical outcomes, stratified by frailty status, in older adults. METHODS: From Taiwan's National Health Insurance research database, a group-based multi-trajectory modelling was adopted to identify distinct longitudinal patterns of polypharmacy composition among older adults with polypharmacy. Cox proportional hazards models were used to assess the association between polypharmacy patterns and subsequent 6-year risk of all-cause mortality, all-cause hospitalisation, unplanned hospitalisation and fracture-specific hospitalisation. FINDINGS: Among 787 072 older adults (mean [SD] age, 76.2 [7.0] years; 361,767 [46.0%] male), we identified three distinct polypharmacy composition patterns: cardiometabolic medications dominant (44·2%; mean of 5.6 cardiometabolic versus 0.9 symptomatic treatment and 0.3 psychotropic medications), symptomatic treatment medications dominant (25·6%; mean of 1.9 cardiometabolic versus 3.2 symptomatic treatment and 1.2 psychotropic medications), and cardiometabolic and symptomatic treatment medications dominant (30·2%; mean of 5.6 cardiometabolic versus 3.4 symptomatic treatment and 1.0 psychotropic medications). These medication patterns remained stable throughout the 2-year trajectory period across all groups. Compared to the cardiometabolic medications dominant group, the symptomatic treatment medications dominant group and the cardiometabolic and symptomatic treatment dominant groups had higher risks of all-cause mortality (adjusted HR 1·22 [95% CI 1·21-1·23] and 1·16 [1·15-1·18]), all-cause hospitalisation (1·09 [1·09-1·10] and1·08 [1·07-1·09]), unplanned hospitalisation (1·07 [1·06-1·08] and 1·08 [1·07-1·09]), and fracture-specific hospitalisation (1·20 [1·18-1·22] and 1·09 [1·07-1·11]). Risk differences attenuated with increasing frailty, except for fracture-specific hospitalisation. INTERPRETATION: Symptomatic treatment medications dominant patterns were associated with higher risks of adverse outcomes, with these associations generally attenuating with increasing frailty severity, except for fracture risk.
引用
- Lin LY, Hsiao FY, Huang ST, et al. Multi-trajectories of polypharmacy composition and clinical outcomes by frailty status: a longitudinal cohort study. Age Ageing. 2025. PMID: 41317080. doi:10.1093/ageing/afaf336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。